Tempest Therapeutics, Inc. Research and Development Asset Acquired Other than Through Business Combination, Written-off
Tempest Therapeutics, Inc. (TPST) reported Research and Development Asset Acquired Other than Through Business Combination, Written-off of $19.93 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff · last filed 2026-08-13
- Tempest Therapeutics, Inc. research and development asset acquired other than through business combination, written-off for the quarter ending 2026-06-30 was $0.00.
- Tempest Therapeutics, Inc. research and development asset acquired other than through business combination, written-off for the quarter ending 2026-03-31 was $19.93M.
- Tempest Therapeutics, Inc. research and development asset acquired other than through business combination, written-off for the quarter ending 2025-06-30 was $0.00.
- Tempest Therapeutics, Inc. research and development asset acquired other than through business combination, written-off for the quarter ending 2025-03-31 was $0.00.
| Period end | Research and Development Asset Acquired Other than Through Business Combination, Written-off 3 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 6 month |
|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $19.93M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $19.93M 10-Q · filed 2026-05-14 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $0.00 10-Q · filed 2026-08-13 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B |